Model and Primary Products in Development Petros was incorporated in Delaware on May 14, 2020, for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (as amended, the Merger Agreement ), by and between Petros, Neurotrope, Inc., a Nevada corporation ( Neurotrope ), Metuchen Pharmaceuticals LLC, a Delaware limited liabilit…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$3M
▲ +113.4% YoY
Op. Margin
–
ROIC
-123.26%
▼ -21.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$4M
▼ -156.3% YoY
Op. Cash Flow (TTM)
-$4M
▼ -158.7% YoY
Net Debt
-$3M
Net Cash Position
Cash & Equiv.
$3M
3Y CAGR: -13.2%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with PTPI
Petros Pharmaceuticals (PTPI) in three numbers
Questions about Petros Pharmaceuticals
Is Petros Pharmaceuticals (PTPI) overvalued?
Petros Pharmaceuticals trades at 0.00 times earnings. Intrinsiqq's fair value calculator has no opening value for PTPI, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Petros Pharmaceuticals a high-quality business?
Petros Pharmaceuticals scores 35 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 7 checks computed from SEC filings. Its best check is margin trend at +140.5pp, and its weakest is return on capital at -123.3%. The Quality tab shows every check against its target.
Does Petros Pharmaceuticals (PTPI) pay a dividend?
No. Petros Pharmaceuticals (PTPI) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 13 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in PTPI's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PTPI
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.